KCNMA1: Calcium-activated potassium channel subunit alpha-1
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+).
- Drugs that act on it: 3
- Approved: 0
- In phases 1 to 3: 3
- Sponsors: 0
Who is on it, and how far along
Every drug ChEMBL records acting on KCNMA1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 3
| Flindokalner | Phase 3 | — | Small molecule | OpenerCalcium-activated potassium channel subunit alpha-1 opener | 0 |
| Andolast | Phase 2 | — | Small molecule | ActivatorCalcium-activated potassium channel subunit alpha-1 activator | 0 |
| BMS-223131 | Phase 2 | — | Small molecule | ActivatorCalcium-activated potassium channel subunit alpha-1 activator | 0 |
- Generalized epilepsy-paroxysmal dyskinesia syndrome0.83
- Liang-Wang syndrome0.73
- Cerebellar atrophy, developmental delay, and seizures0.71
- Idiopathic generalized epilepsy0.60
- Hereditary disease0.50
- Myopia0.49
- Refractive error0.49
- Osteoarthritis, hip0.39
- Epileptic encephalopathy0.37
- Obesity disorder0.34
- Eye disorder0.33
- Diabetes mellitus0.33
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4304, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt Q12791, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets